Alterity Therapeutics (NASDAQ:ATHE) Earns Buy Rating from Analysts at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH assumed coverage on shares of Alterity Therapeutics (NASDAQ:ATHE) in a research note issued to investors on Tuesday. The brokerage set a “buy” rating and a $10.00 price target on the stock. LADENBURG THALM/SH SH’s price target indicates a potential upside of 125.99% from the company’s current price.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Alterity Therapeutics in a research report on Monday, April 20th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $10.00.

Alterity Therapeutics Trading Up 5.1%

Shares of NASDAQ ATHE traded up $0.22 during trading on Tuesday, reaching $4.43. 952 shares of the stock were exchanged, compared to its average volume of 1,173. The business’s 50-day moving average price is $4.23 and its 200 day moving average price is $3.66. Alterity Therapeutics has a twelve month low of $4.14 and a twelve month high of $350.00.

Institutional Investors Weigh In On Alterity Therapeutics

An institutional investor recently bought a new position in Alterity Therapeutics stock. Citadel Advisors LLC purchased a new stake in shares of Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 22,144 shares of the company’s stock, valued at approximately $83,000. Citadel Advisors LLC owned approximately 0.25% of Alterity Therapeutics at the end of the most recent quarter. 2.14% of the stock is currently owned by institutional investors.

About Alterity Therapeutics

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.